'COVID-19 & Down Syndrome Resource'

NTG Joins with National Groups in Issuing Updated Resource on COVID-19 and Down Syndrome

With the continuation of the COVID-19 pandemic in the United States, the NTG has joined with several Down syndrome national organizations to produce and issue an updated resource on COVID-19 and Down syndrome 

The resource is available in both English and Spanish

The resource provides up-to-date information on COVID-19 and its variants, testing, vaccinations, and wellness for families and others concerned with the impact of COVID-19 upon persons of all ages with Down syndrome




The English Resource is the 16 November 2021 version


The Spanish Resource is the 1 March 2021 version

T21RS Studies

​T21RS issues statement regarding COVID-19 booster vaccination for individuals with Down syndrome...

Analysis of various data sources collected during the COVID-19 pandemic has established that individuals with Down syndrome are at increased risk for both hospitalisation and mortality after infection with SARS-CoV-2. Adults with Down syndrome were amongst the highest risk groups for mortality. Furthermore, there have been concerns that, when admitted to hospital during peak infection periods and when demands on resources are high, people with disabilities and long-term conditions may not be prioritised for access to scarce resources such as respiratory ventilation or intensive care beds. 


It has been the clinical experience of many Down syndrome clinics in different countries that COVID-19 vaccines can be safely given to children (from age 12) and adults with Down syndrome.  There are also reasonable indications that full vaccination offers significant protection against the poor outcomes associated with infection in people with Down syndrome. However, based on our understanding of the immune response in Down syndrome, including reduced numbers of and differences in memory B cell responses, and previously published studies on the immunological response of those with Down syndrome to other vaccines, their antibody response to vaccination may be less robust when compared to peers without Down syndrome. 


We therefore recommend that individuals with Down syndrome should be amongst those prioritised for booster vaccination for persistent production of antibodies against COVID19 antigen. There have been some indications of additional benefit by combining vaccines from different sources (e.g. Pfizer and Moderna, or Moderna and AstraZeneca) to promote better immune responses based upon studies in the general population, but any booster is preferable to none.

29 November 2021

T21RS image_edited.jpg
NTG Involvement in COVID-19 studies
NTG Collaborative Study of COVID-19 Impact on Provider Agencies

The aim of this internet-based survey was to obtain information from community-based organizations (CBOs) affiliated with ACCSES, a national provider association based in Washington DC, as to what types of difficulties provider agencies were encountering during a transitional phase of the coronavirus COVID-19 pandemic. The study was conducted in collaboration with the University of Illinois at Chicago in the summer of 2020.

Key Findings
  • CBOs providing direct services noted experiencing contagion, lockdowns, loss of staff, challenges in obtaining PPEs, and lack of state or federal guidance.

  • Maintaining safe living environments and coping with infected staff and clientele were urgent concerns.

  • CBOs reported financial and clinical support challenges, as well as staffing problems.

  • Testing availability, lack of sufficient PPEs, dealing with clientele and staff boredom during lockdowns, and increased costs for equipment and staff (with no commensurate increases in fees) were noted as problems.

  • Re-opening challenges were reported, including funding, staffing, PPEs, liability, and lack of guidance. CBOs found ways to work-around some programmatic issues, by using telehealth, drive-by visits, instituting rigorous safety measures, and offering virtual services, when possible

Cover pages-Impact of COVID-19 on Provid